Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-Line Anti-EGFR Therapy to Facilitate Retreatment in Metastatic Colorectal Cancer
NCT04587128Phase 2Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2020
- Primary completion
- Oct 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab and KL-140 in colorectal cancer (CRC) (3 cohorts), sponsored by University of Wisconsin–Madison. Primary endpoints: Disease Control Rate at 6 months and Progression Free Survival up to 4 years. Started Oct 2020; status: active, not recruiting.
02
Drugs
panitumumabKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04587128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587128.